Gene editing treats a mouse model of a neurodevelopmental disorder

Nature News · Feb 18, 2026 · Collected from RSS

Full Article

NEWS AND VIEWS 18 February 2026 An approach that specifically targets a single nucleotide corrected behavioural abnormalities in an animal model of Snijders Blok–Campeau syndrome. By Kevin J. Bender Kevin J. Bender is in the Department of Neurology, University of California, San Francisco, San Francisco, California 94158, USA. Genetic variants in the CHD3 gene underlie a neurodevelopmental disorder called Snijders Blok–Campeau syndrome. Writing in Nature, Yang et al.1 have developed a gene-editing approach — directly altering a mutated base in a DNA sequence — that restores CHD3 function in mice harbouring a mutation that is commonly observed in children with the disorder. These promising results might pave the way for the development of an effective clinical treatment. Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support doi: https://doi.org/10.1038/d41586-026-00291-8 ReferencesYang, K. et al. Nature https://doi.org/10.1038/s41586-026-10113-6 (2026).Article Google Scholar Alendar, A. & Berns, A. Gene Dev. 35, 1403–1430 (2021).Article PubMed Google Scholar Gillentine, M. A., Wang, T. & Eichler, E. E. Biomedicines 10, 2865 (2022).Article PubMed Google Scholar Drivas, T. G. et al. Eur. J. Hum. Genet. 28, 1422–1431 (2020).Article PubMed Google Scholar Almeida, M. C. et al. Neuron 112, 1778–1794 (2024).Article PubMed Google Scholar Coe, B. P. et al. Nature Genet. 51, 106–116 (2019).Article PubMed Google Scholar Musunuru, K. et al. N. Engl. J. Med. 392, 2235–2243 (2025).Article PubMed Google Scholar Wang, C. et al. Nature Mater. 24, 1653–1663 (2025).Article PubMed Google Scholar Download references Competing Interests K.J.B. is a member of the Scientific Advisory Board of Regel Therapeutics and has received research funding from BioMarin Pharmaceutical in the past two years. Related Articles Read the paper: In vivo base editing of Chd3 rescues behavioural abnormalities in mice A baby benefits from personalized gene editing in the clinic AI expands the repertoire of CRISPR-associated proteins for genome editing See all News & Views Subjects Latest on: Medical research Gene therapy Neuroscience AI offers way to image and assess clinical cell samples News & Views 18 FEB 26 AI succeeds in diagnosing rare diseases News & Views 18 FEB 26 CAR-T therapy provides relief for children with autoimmune diseases Research Highlight 13 FEB 26 In vivo base editing of Chd3 rescues behavioural abnormalities in mice Article 18 FEB 26 Mimicking opioid analgesia in cortical pain circuits Article 07 JAN 26 Science in 2026: the events to watch for in the coming year News 18 DEC 25 How do autistic people age — and what does it mean for their health? News Feature 18 FEB 26 Single-cell and isoform-specific translational profiling of the mouse brain Article 18 FEB 26 Agouti integrates environmental cues to regulate paternal behaviour Article 18 FEB 26